Immunocore Holdings plc
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
IMCR$32.38+2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets as of and
Condensed Consolidated Balance Sheets
(Unaudited) (In thousands, except share and per share data)
| June 30,2025 | December 31,2024 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $487,933 | $455,731 |
| Marketable securities | 394,878 | 364,645 |
| Accounts receivable, net | 69,761 | 63,009 |
| Prepaid expenses and other current assets | 44,270 | 41,033 |
| Inventory, net | 5,456 | 5,446 |
| Total current assets | 1,002,298 | 929,864 |
| Property and equipment, net | 9,548 | 10,092 |
| Operating lease right of use assets, net | 39,428 | 37,643 |
| Deferred tax assets, net | 14,077 | 14,790 |
| Other non-current assets | 17,036 | 17,117 |
| Total assets | $1,082,387 | $1,009,506 |
| Liabilities and shareholders’ equity | ||
| Current liabilities | ||
| Accounts payable | $23,856 | $25,100 |
| Accrued expenses and other current liabilities | 143,785 | 185,534 |
| Deferred revenue, current | 594 | — |
| Operating lease liabilities, current | 1,843 | 1,547 |
| Total current liabilities | 170,078 | 212,181 |
| Accrued expenses, non-current | 83,960 | — |
| Deferred revenue, non-current | 5,247 | 5,434 |
| Operating lease liabilities, non-current | 42,561 | 40,162 |
| Interest-bearing loans and borrowings | 392,060 | 391,013 |
| Total liabilities | 693,906 | 648,790 |
| Commitments and contingencies (Note 10) | ||
| Shareholders’ equity | ||
| Ordinary shares (voting and non-voting), £0.002 par value, most recent authority to allot up to a maximum nominal value of £149,633 and £97,454 shares as of June 30, 2025 and December 31, 2024, respectively, and 50,372,068 and 50,064,860 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively. | 135 | 135 |
| Deferred shares, £0.0001 par value, 5,793,501 shares authorized, issued and outstanding as of June 30, 2025 and December 31, 2024. | 1 | 1 |
| Additional paid-in capital | 1,215,997 | 1,190,104 |
| Accumulated deficit | (801,038) | (795,761) |
| Accumulated other comprehensive loss | (26,614) | (33,763) |
| Total shareholders' equity | 388,481 | 360,716 |
| Total liabilities and shareholders' equity | $1,082,387 | $1,009,506 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.